The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | MRD-driven immunotherapy in early stage follicular lymphoma
Alessandro Pulsoni, MD, Sapienza University of Rome, Rome, Italy, outlines the FIL_MIRO study (NCT02710643). This phase II, multicenter trial combines local radiotherapy and measurable residual disease (MRD) driven immunotherapy in early stage follicular lymphoma. The first results of the study show that MRD negativity after immunotherapy with an anti-CD20 monoclonal antibody, ofatumumab, was achieved. Prof. Pulsoni mentions that a longer follow-up will allow to conclusively define the impact of the MRD-driven strategy on clinical outcome. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
